Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics is attractive because its partnered assets are already de-risked and monetizing, with $274.4M in 3Q26 collaboration revenue, $3.07 diluted EPS, and $834.6M in cash and investments supporting both development and a $300M buyback. Icotyde’s rapid launch, broad coverage, and more than 20,000 patients initiated across nearly 9,000 prescribers validate strong commercial demand, while Mimrylo adds a second royalty stream with 14%–29% economics and up to $875M in milestones. Beyond the approved franchises, wholly owned programs like PN-881, PN-477, and PN-8047 offer large upside through differentiated oral peptide approaches in validated disease pathways, creating a capital-light growth platform with multiple shots on goal.

Protagonist Therapeutics is exposed to a heavy mix of commercial, clinical, regulatory, and financial risk, with valuation largely dependent on partnered assets and execution by Johnson & Johnson and Takeda. Its wholly owned pipeline still faces the classic late-stage attrition problem: early promise for rusfertide, PN-881, and Icotyde may not translate into approval or differentiation, especially in crowded I&I and PV markets where efficacy remains the key bar. Competition, including other oral IL-23 and TMPRSS6 programs, could compress uptake and share, while higher-than-expected R&D spending and unpredictable regulatory decisions further weaken the investment case.